BioLineRx (BLRX) Total Liabilities (2012 - 2025)

BioLineRx's Total Liabilities history runs 14 years deep, the most recent figure standing at $17.6 million for Q4 2025.

• In Q4 2025, Total Liabilities fell 30.99% year-over-year to $17.6 million; the TTM figure through Dec 2025 stood at $17.6 million (down 30.99% YoY), while the FY2025 annual figure was $17.6 million, down 30.99% from the prior year.
• Total Liabilities was $17.6 million for Q4 2025 at BioLineRx, down from $20.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $50.7 million in Q4 2023 to a low of $11.3 million in Q2 2022.
• Historically, Total Liabilities has averaged $27.0 million across 5 years, with a median of $24.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities jumped 236.13% in 2023, then slumped 54.18% in 2025.
• A 5-year view of Total Liabilities shows it stood at $13.3 million in 2021, then soared by 91.99% to $25.5 million in 2022, then soared by 98.5% to $50.7 million in 2023, then slumped by 49.81% to $25.4 million in 2024, then tumbled by 30.99% to $17.6 million in 2025.
• The last three Total Liabilities figures came in at $17.6 million (Q4 2025), $20.3 million (Q3 2025), and $23.2 million (Q2 2025), per Business Quant data.